His-Purkinje conduction system pacing (HPCSP) clinical outcomes, including mortality and morbidity of heart failure hospitalization, are reviewed for various pacing indications.
What are the clinical outcomes of His-Purkinje conduction system pacing in patients requiring pacing?
This review summarizes the clinical outcomes, including mortality and heart failure hospitalization, associated with His-Purkinje conduction system pacing.
His-Purkinje conduction system pacing (HPCSP) in the form of His bundle pacing (HBP) and left bundle branch pacing (LBBP) allows normal left ventricular activation, thereby preventing the adverse consequences of right ventricular pacing. HBP has been established for several years with centers from China, Europe, and North America reporting their experience. There is international guidance as to how to implant such systems with the differing patterns of His bundle capture clearly described. LBBP is a more recent innovation with potential advantages including improved pacing parameters. HPCSP has been extensively studied in a variety of indications including cardiac resynchronization therapy, atrioventricular node ablation, and bradycardia pacing. This review will focus on the clinical outcomes of HPCSP including mortality and morbidity of heart failure hospitalization and symptoms.
Muthumala et al. (Wed,) conducted a review in Cardiac resynchronization therapy, atrioventricular node ablation, and bradycardia pacing. His-Purkinje conduction system pacing (HPCSP) was evaluated on Clinical outcomes including mortality and morbidity of heart failure hospitalization and symptoms. His-Purkinje conduction system pacing (HPCSP) clinical outcomes, including mortality and morbidity of heart failure hospitalization, are reviewed for various pacing indications.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: